Retatrutide
RT30
Lyophilized peptide for use under a licensed healthcare provider. Choose single ampule/vial or box of 10. Sourced via Ares Technology Limited (Hong Kong) / Healthtide Biotech manufacturing list dated 7 October 2026. Specification: 30 mg × 10 vials.
- • Prescription / clinician-supervised pathway
- • Same LIRAVEXIN cart and checkout as pen packages
- • Not medical advice — individual suitability is determined by your clinician
Clinical reference (clinician-supervised)
Retatrutide (LY3437943) has been evaluated in phase 2 obesity trials published in the New England Journal of Medicine, showing substantial mean weight reduction at 24 and 48 weeks with dose-related gastrointestinal adverse events. It is also studied in type 2 diabetes and related metabolic programs. Status remains investigational pending later-phase outcomes and regulatory decisions. On the LIRAVEXIN soft catalog it is framed strictly as a clinician-supervised, prescription-pathway candidate—not consumer self-administration. Any use requires informed consent about investigational status where applicable.
Phase 2 obesity trial maintenance arms used approximately 1, 4, 8, or 12 mg subcutaneously once weekly, with gradual escalation (often starting 2 mg vs 4 mg) every ~4 weeks to improve tolerability. There is no FDA-approved labeled dose.
Once weekly SC in published trials.
Subcutaneous (trial).
Typical clinical / literature ranges under clinician supervision — not a prescription and not a DIY dosing guide. Individual dosing is determined solely by the treating clinician.
Liravexin USD for this pack (wholesale comparison · source × 3). Item is added to your shared cart for checkout coordination with your clinician pathway.
Or continue to checkout →